Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia
Status: Recruiting
Location: See all (18) locations...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure)
• Age \> 18 years old
• Patient able to understand and agree to participate in the study
• Affiliation to a social security system
Locations
Other Locations
France
CHU d'Angers
NOT_YET_RECRUITING
Angers
CHU de Bordeaux
NOT_YET_RECRUITING
Bordeaux
Hôpital Ambroise Paré
NOT_YET_RECRUITING
Boulogne-billancourt
CHU de Caen Normandie
NOT_YET_RECRUITING
Caen
CHU clermont-ferrand
RECRUITING
Clermont-ferrand
CHU de Dijon
NOT_YET_RECRUITING
Dijon
CHRU de Lille
NOT_YET_RECRUITING
Lille
Hospices Civiles de Lyon
NOT_YET_RECRUITING
Lyon
Assistance Publique - Hôpitaux de Marseille
NOT_YET_RECRUITING
Marseille
CHU de Montpellier
NOT_YET_RECRUITING
Montpellier
CHU de Nancy
NOT_YET_RECRUITING
Nancy
CHU de Nantes
NOT_YET_RECRUITING
Nantes
CHU de Nice
NOT_YET_RECRUITING
Nice
AP-HP - Hôpital Ténon
NOT_YET_RECRUITING
Paris
CHU de Poitiers
NOT_YET_RECRUITING
Poitiers
CHU de Rennes
NOT_YET_RECRUITING
Rennes
CHRU de Strasbourg
NOT_YET_RECRUITING
Strasbourg
CHU de Toulouse
NOT_YET_RECRUITING
Toulouse
Contact Information
Primary
Lise Laclautre
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Time Frame
Start Date: 2023-04-07
Estimated Completion Date: 2029-04
Participants
Target number of participants: 100
Treatments
Other: Cohort study
a single arm, the anticoagulant and/or antiplatelet treatment is not conditioned by the study
Related Therapeutic Areas
Sponsors
Leads: University Hospital, Clermont-Ferrand